Riley Lovendale

Riley Lovendale is a counsel in Goodwin’s Strategic Technology Transactions and Licensing practice and a member of the firm’s Technology and Life Sciences group. He concentrates on technology and intellectual property transactions, including licensing, collaboration, strategic alliance, joint development, reseller and other commercial agreements; and due diligence and other intellectual property issues in mergers, acquisitions and venture capital and private equity transactions. Mr. Lovendale also regularly counsels companies with respect to intellectual property issues. His experience also encompasses public offerings, including those involving foreign issuers seeking to access the U.S. capital markets, and counseling both U.S. and non-U.S. companies with respect to SEC reporting and securities law compliance. He joined Goodwin in 2014.

Mr. Lovendale’s representative clients and transactions include:

Mergers and Acquisitions

• 6 River Systems, regarding intellectual property matters, in its sale to Shopify
• Charlesbank Capital Partners, LLC, regarding intellectual property matters, in its respective investments in, or purchases of, a variety of technology and other companies
• Continuum Managed Services, LLC, regarding intellectual property matters, on its sale to an entity controlled by Thoma Bravo, LLC from Summit Partners
• EPR Properties, regarding intellectual property matters, in its acquisition of CNL Lifestyle Properties together with a co-buyer, Och-Ziff Real Estate
• Semma Therapeutics, Inc. in its acquisition of CytoSolv, Inc., a developer of encapsulating cell technology
• SimpliSafe, regarding intellectual property matters, in its sale to Hellman & Friedman
• Taconic Biosciences, regarding intellectual property matters, in its sale to H.I.G. Capital

Public Offerings

• argenx SE in its $115 million initial U.S. public offering and $266 million follow-on offering
• BeiGene, Ltd. in its $182 million initial U.S. public offering and $200 million, $201 million and $800 million follow-on offerings
• Celyad SA in its $54 million follow-on offering
• ConforMIS, Inc. in its $23 million follow-on offering
• Galapagos NV in its $275 million initial U.S. public offering and $371 million follow-on offering
• Intellia Therapeutics, Inc. in its $150 million follow-on offering

Private Financings

• Naurex, Inc. in its $80 million Series C financing
• RaNA Therapeutics, LLC in its $55 million Series B financing
• Semma Therapeutics, Inc. in its $44 million Series A financing and $114 million Series B financing

Prior to joining Goodwin, Mr. Lovendale served as a legal intern at The Law Office of Zick Rubin (now Rubin & Ulrich LLC)—a firm specializing in publishing law, copyright, trademark and intellectual property issues in higher education—and Community Action Program Legal Services, Inc. (CAPLAW).

Mr. Lovendale’s speaking engagements include:

• “Doing Business Online,” BizGrow (2017) and Neighborhood Business Initiative workshops (2017, 2019)

While in law school, Mr. Lovendale was a senior editor for the Boston College Law Review. His article, “Tax vs. Penalty, Round Two: Interpreting the ACA’s Assessable Payment as a Tax for Federal Award Cost Allowances,” 55 B.C.L. Rev. 947 (2014), was informed by his experience at CAPLAW working with nonprofits receiving federal grants when the U.S. Supreme Court issued its 2012 opinion on the Patient Protection and Affordable Care Act in National Federation of Independent Business v. Sebelius.